Application of muscle relaxant antagonists
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients undergoing laparoscopic radical liver cancer surgery under general anesthesia; 2. Postoperative application of sugammadex to antagonize the residual effect of rocuronium muscle relaxation; 3. Aged 18 to 65 years old male or female; 4. ASA rating: Level I - Level III; 5. 18kg/m2 <= BMI <= 27.9 kg/m2; 6. Voluntary signing of informed consent; 7. Non-lactating women, women of childbearing age must have a negative pregnancy test.
Exclusion criteria
Exclusion criteria: 1. Patients who are allergic to rocuronium and sugammadex; 2. Patients with central and peripheral nervous system diseases, such as polio, Parkinson's disease, peripheral neuropathy, etc.; 3. Patients with neuromuscular diseases: multiple sclerosis, myasthenia gravis, atrophic myotonia, etc.; 4. Diaphragm dysfunction, pneumothorax, pleural effusion, mediastinal gas; 5. Pregnant or breastfeeding women; 6. The investigator judged that the patient was not eligible for the other conditions of the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative residual incidence of muscle relaxation;Baseline recovery rate of diaphragm; | — |
Secondary
| Measure | Time frame |
|---|---|
| Muscle relaxation recovery time;PACU monitoring time;Postoperative extubation time;Intraoperative rocuronium dosage;Adverse reactions and pulmonary complications 7 days after surgery; | — |
Countries
China
Contacts
Union Hospital, Tongji Medical College, Huazhong University of Science & Technology